Denali Therapeutics Inc.
DNLI$1.90B
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSOUTH SAN FRANCISCO517 employees
Drugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Dec 15, 2026
30wMarket Overview
Stock performance and key metrics
DNLI News
Catalyst Timeline
2 upcoming, 1 past
Drug Pipeline
idursulfase
Mucopolysaccharidosis II
tividenofusp alfa
Mucopolysaccharidosis II
DNL126
Mucopolysaccharidosis Type IIIA
DNL593
Frontotemporal Dementia
BIIB122 225 mg
Parkinson Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
idursulfase | Phase 3 | Mucopolysaccharidosis II | - | - |
tividenofusp alfa | Phase 3 | Mucopolysaccharidosis II | - | - |
DNL126 | Phase 2 | Mucopolysaccharidosis Type IIIA | - | - |
DNL593 | Phase 2 | Frontotemporal Dementia | - | - |
BIIB122 225 mg | Phase 2 | Parkinson Disease | - | - |
Mucopolysaccharidosis II
2 drugs in this indication
Mucopolysaccharidosis Type IIIA
1 drug in this indication
Frontotemporal Dementia
1 drug in this indication
Parkinson Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply